Biocytogen and Gilead Partner for Multi-Target Antibody Collaboration
Biocytogen and Gilead Enter Into a Multi-Target Antibody Evaluation and Option Agreement Introduction Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has recently announced an exciting new partnership with Gilead Sciences, Inc. The agreement entails an antibody evaluation and option agreement that will allow Gilead access to Biocytogen’s extensive fully human antibody library generated against…